CRANBURY, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the 25th Annual Oppenheimer Healthcare Conference in New York, NY on Thursday, December 11, 2014 at 1:35 p.m. ET.
A live webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate web site at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat) in combination with ERT for Pompe disease.
CONTACT: Sara Pellegrino Director, Investor Relations firstname.lastname@example.org (609) 662-5044
Source:Amicus Therapeutics, Inc.